China's New YY/T Standards for Copper Tripeptide-1 and Acetyl Hexapeptide-8: What Buyers Should Know

Two of China's five new cosmetic ingredient standards are peptides

On 3 April 2026 China's National Medical Products Administration issued Announcement No. 34 of 2026, releasing five cosmetic industry standards. All five are new documents. All five take effect on 1 May 2027.

Two single-ingredient peptide standards. If you buy copper peptide or acetyl hexapeptide-8 from China, these are the two documents that will start appearing in supplier conversations.

One practical note before anything else: the full texts are free. They are published as attachments to the announcement itself, not sold. If a supplier tells you the standard is a paid document they have not obtained, that is a five-minute download they have not done.

What YY/T 10005 requires for Tripeptide-1 Copper

The standard applies to Tripeptide-1 Copper and its salts for cosmetic use. Its identity block matches what we already publish on our Copper Tripeptide-1 ingredient page: INCI name COPPER TRIPEPTIDE-1, CAS 89030-95-5, formula C₁₄H₂₂CuN₆O₄, relative molecular mass 401.91.

The physicochemical requirements are where it gets useful:

The acceptance limit changes by 13 percentage points depending on salt form. A quotation stating "content ≥ 91%" and one stating "content ≥ 78%" can both be conformant, because they describe different materials. Without the salt form stated in the specification, the reported content values are not directly comparable.

This is the concrete version of a problem we have written about generally in peptide content versus total vial weight and, for copper specifically, in copper content versus purity percentage. The standard now puts numbers on it.

Microbiological and contaminant limits are shared with the acetyl hexapeptide-8 standard: total plate count ≤ 1 000 CFU/g, yeast and mould ≤ 100 CFU/g, thermotolerant coliforms, Staphylococcus aureus and Pseudomonas aeruginosa not detected; mercury ≤ 1, lead ≤ 10, arsenic ≤ 2, cadmium ≤ 5 mg/kg, methanol ≤ 2 000 mg/kg.

The method detail most people will get wrong

Annex A of YY/T 10005 is normative, and it determines copper and tripeptide-1 by the same HPLC run — C18 column (4.6 × 250 mm, 5 μm or equivalent), detection at 220 nm, 0.1% TFA in water and 0.1% TFA in acetonitrile as mobile phases, gradient elution, external standard peak area. Purity comes from the same chromatogram; clause 6.4 simply points back to it.

That matters because the intuitive assumption is wrong. Copper content sounds like an elemental question, and elemental methods — ICP-MS, ICP-OES, AAS — are what most people reach for. Those give you total copper. The standard's figure is not that. If you are comparing a supplier's copper number against the ≥ 13.0% limit, ask which method produced it before concluding anything.

A related question that buyers increasingly raise — how much of the copper is tightly complexed rather than labile — is a different question again, has no universal pharmacopoeial method, and is not covered by this standard. Our position on what can and cannot be claimed there, including where we decline to promise numbers, is set out in free copper in GHK-Cu.

What YY/T 10004 requires for Acetyl Hexapeptide-8 — and who it deliberately excludes

Identity: INCI ACETYL HEXAPEPTIDE-8, CAS 616204-22-9, sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂, relative molecular mass 888.42. For the wider procurement picture on this ingredient, see how B2B buyers should evaluate acetyl hexapeptide-8.

One apparent discrepancy deserves clarification. The standard states a relative molecular mass of 888.42, while some supplier documentation reports approximately 888.99 for the same formula. Before treating the difference as an identity discrepancy, verify the mass convention and calculation basis used in each document.

Two things deserve attention here.

First, the scope is narrower than the title suggests. The standard applies to acetyl hexapeptide-8 powder or friable cake, in acetate or salt-free form, synthesised from glutamic acid, methionine, glutamine and arginine and finished by purification and lyophilisation. It states explicitly that it does not apply to aqueous, pre-dissolved forms, or to analogues of other amino acid sequences.

A large part of what is sold as acetyl hexapeptide-8 on the open market is a pre-dissolved solution, often labelled with a percentage that describes the solution rather than the active. Those materials are outside this standard's scope. That is not a judgement about whether they are fit for a given formulation — it is a statement about what can and cannot be measured against this industry standard. If conformance to YY/T 10004 matters to your specification, the material has to be in a form the standard covers.

Second, TFA is now a specified limit. Trifluoroacetic acid is a residue of the synthesis and purification route, not an ingredient, and it has historically been something buyers had to know to ask about. At ≤ 5.0% it is now a line item. We have written separately about TFA-removed material and acetate counterion analysis; the short version is that "TFA removed" is a claim that should come with a method and a number, and now there is a reference number to compare against.

Third, lyophilisation does not by itself demonstrate the absence of residual solvents. The reasoning sounds right — freeze-drying is the last step, so whatever was there has gone. But acetonitrile is the mobile phase of the preparative purification that precedes it, and solvents used earlier in purification can remain measurable in finished material. That is why YY/T 10004 sets explicit limits for methanol, ethanol and acetonitrile rather than treating the process step as sufficient evidence. A certificate that omits residual solvents on the grounds that the product is lyophilised has offered a process argument, not a result.

The two standards do not ask for the same logistics

This is the clause most likely to be skipped and most likely to cost money, because the two peptides are treated differently.

For copper peptide this is unremarkable. For acetyl hexapeptide-8 it is a procurement decision: refrigerated transport on an international lane changes freight cost, packaging, lead time and what happens when a shipment sits on a tarmac. It also changes what a shelf life claim is worth — both standards tie shelf life to the stated transport and storage conditions being met, so a shipment that has been outside them has left the basis of its own shelf life behind.

Worth asking before the first order rather than after the first excursion.

The standard makes the purity–content distinction explicit

Buried in a note under Table 2 of YY/T 10004 is the clearest official statement of something that costs buyers real money:

Purity expresses the proportion of the active ingredient among the active ingredient and organic impurities. Content expresses the proportion of the active ingredient in the entire product.

Purity and content are not two words for the same thing, and a certificate that reports only one of them has told you half the story. A material can be 98% pure and still be substantially less than 98% of what is in the drum, because water, counterion, residual solvent and inorganic matter are in the product but not in the purity denominator.

We have covered this in purity versus content. The distinction is now stated explicitly in YY/T 10004—2026, giving buyers a common reference point for specification drafting and COA review.

"Recommended" does not mean "ignorable"

YY/T denotes a recommended industry standard rather than a mandatory one. The standards nevertheless provide an official technical reference for ingredient quality control, testing and supplier qualification — the documents themselves state that their technical requirements are intended to serve a guiding role in raw material quality control, product safety assessment and regulatory supervision.

Three things change in practice:

It can become contractually binding when you incorporate it into the agreed specification. Where YY/T 10005—2026 or YY/T 10004—2026 is expressly incorporated into an agreed purchase specification or supply agreement, its requirements can become part of the supplier's contractual obligations, and a delivered lot that misses them is a supply failure rather than a difference of opinion. Incorporating the standard into an agreed specification gives buyers a clear acceptance basis.

It becomes a reference a Chinese supplier is expected to know. Comparing three Chinese quotations used to mean comparing three in-house method sets, each with its own assay basis. There is now a named published standard to point at, and a supplier who cannot say whether their release testing lines up with it has told you something about their quality system.

It gives you a neutral reference. Our own view of what a competent copper peptide certificate should contain is published — but it is our view. A published standard is not anyone's marketing.

What it does not do

• It is a cosmetic ingredient standard. It speaks to material used in cosmetics and makes no statement beyond that framing.
• It does not retroactively change how an earlier certificate was issued. A 2026 certificate issued against a manufacturer's internal specification does not become a YY/T-issued certificate when the standard takes effect. Distinguish between comparing historical test results against the new limits — which can be legitimate — and claiming that the certificate itself was issued against the YY/T standard. Separately, an old certificate does not describe a lot made later, which is why a certificate should belong to the batch you are actually buying.
• It does not audit anyone. A named standard narrows the argument about what to measure. It does not tell you that a given plant measured it, on your batch, with records you can inspect. That is still document review — see our cosmetic peptide supplier qualification checklist, which does not get shorter because of this announcement.

Legacy practice and the new framework are not the same thing

Much of what is normal in peptide raw material documentation today predates these standards. Reporting a total count rather than the named organisms, omitting residual solvents on a lyophilised product, giving heavy metals as a group figure rather than four individual results — these are established practices, and until 1 May 2027 they are not wrong.

They are simply not the same thing as meeting YY/T 10004 or YY/T 10005, which specify five microbiological items, three residual solvents and four individually limited heavy metals. Between now and the effective date, both the practice and the standard will be in circulation, and a buyer comparing documents will encounter both.

The useful posture is not to treat the gap as a failing but to know it exists, and to ask which of the two a given certificate reflects.

Where we stand

We will not claim conformance to a standard that is not yet in force, and we are not going to describe our documentation as something it is not. Here is the accurate position.

Our copper peptide is the hydrochloride. For comparison with YY/T 10005—2026, the hydrochloride limit is therefore the relevant benchmark: tripeptide-1 copper content ≥ 83.0% on an anhydrous basis, not the ≥ 91.0% that applies to salt-free material. Batch documentation for our current material reports content above that limit, along with purity, copper content, pH, water, acetic acid, the five microbiological items and the four heavy metals. If you are comparing our number against a salt-free supplier's number, you are comparing two different materials — which is the whole point of the salt-form clause.

Copper content on our batch documentation is determined by HPLC, not by an elemental method. We checked, because the two answer different questions and we did not want to assume. That is the same class of method the standard's Annex A specifies.

Our acetyl hexapeptide-8 is lyophilised powder, in the form the standard covers. Material supplied as a pre-dissolved solution is outside YY/T 10004's scope entirely, so this is not a small distinction. Specifications for both materials are on their product pages — Copper Tripeptide-1 (GHK-Cu) and Acetyl Hexapeptide-8.

What we are not saying: our current certificates are issued against manufacturer specifications, not against YY/T 10005 or YY/T 10004. Those standards do not take effect until 1 May 2027. Until we have mapped our release testing against them item by item and closed whatever gaps that exercise finds, "conforms to YY/T 10005" is not a sentence we are entitled to write. If a supplier claims alignment before the effective date, ask for the item-by-item evidence behind that claim rather than relying on the statement alone.

What we will do before the effective date is publish that mapping — requirement by requirement, including anything the standard specifies that we do not currently report. A gap you can see is worth more to you than a claim you cannot check.

What to ask a Chinese supplier now

You do not have to wait until 2027. Ten questions, in the order we would ask them:

1. Have you obtained YY/T 10005—2026 (or YY/T 10004—2026)? It is a free download.
2. Which salt form is your material — salt-free, hydrochloride or acetate — and which content limit therefore applies?
3. Which requirements in the standard do you currently test for, and which do you not?
4. For copper content, which method produced the number — the standard's Annex A HPLC procedure, or an elemental method reporting total copper?
5. Is the certificate specific to the lot I am buying, or a reference certificate reused across lots?
6. For acetyl hexapeptide-8: is the material powder or a pre-dissolved solution, and what is the TFA figure and its method?
7. Do the INCI name, trade name and CAS number match across the certificate, the label and the invoice? (Why this is not a trivial question: INCI, trade name and internal code alignment.)
8. Where your current method differs from the standard's method, can you provide the method reference, its validation basis, and a bridging or comparability rationale? This matters more than it sounds: the common case is not "we did not test" but "we tested by a different method", and the two are not interchangeable.
9. Do your labelled storage and transport conditions match the applicable requirements — and for acetyl hexapeptide-8, how do you maintain 2 °C – 8 °C on an international lane and how are temperature excursions documented?
10. Will you accept the standard as a referenced specification in the purchase agreement, and what deviations would you want written in?

The final question is particularly useful because it tests whether the supplier is willing to convert a quality claim into an agreed acceptance criterion.

FAQ

Are YY/T 10005—2026 and YY/T 10004—2026 mandatory?

No. YY/T denotes a recommended industry standard rather than a mandatory one. It can become contractually binding where the parties expressly incorporate it into the agreed purchase specification or supply agreement.

When do they take effect?

1 May 2027. Both were issued on 3 April 2026 under NMPA Announcement No. 34 of 2026, alongside three other cosmetic ingredient standards.

Do I have to buy the standard to read it?

No. Both texts are published free as attachments to the announcement.

Why do two suppliers quote different content limits for copper peptide?

Because the limit depends on salt form: ≥ 91.0% for salt-free, ≥ 83.0% for the hydrochloride, ≥ 78.0% for the acetate, on an anhydrous basis. Specify the salt form or the number is not comparable.

Is copper content measured by ICP?

Not under this standard. Annex A determines copper and tripeptide-1 together by HPLC with UV detection at 220 nm. Elemental methods report total copper, which is a different measurement.

Does the acetyl hexapeptide-8 standard cover pre-dissolved solutions?

No. It covers powder or friable cake in acetate or salt-free form, and states explicitly that it does not apply to aqueous or pre-dissolved forms, or to analogues of other sequences.

The material is freeze-dried — are residual solvents still relevant?

Yes. Purification with acetonitrile-based mobile phases precedes lyophilisation, and solvents used at that stage can remain measurable in the finished material. YY/T 10004 sets limits for acetonitrile, ethanol and methanol rather than treating the process step as proof.

Do the two standards have the same storage and shipping requirements?

No. Tripeptide-1 copper may be transported at ambient temperature and stored protected from light, dry and sealed at ambient. Acetyl hexapeptide-8 requires 2 °C – 8 °C refrigerated transport, with 2 °C – 8 °C for long-term storage. Both tie shelf life to those conditions being met.

Does a standard existing mean Chinese peptide raw material is now reliable?

No. A standard tells you what to measure. It does not tell you that a particular supplier measured it, on your batch, with records you can inspect. Document review does not get easier; it gets better defined.